What is the appropriate assessment and management plan for a 66‑year‑old female with stage IV intrahepatic cholangiocarcinoma (splenic metastasis) receiving durvalumab, gemcitabine and cisplatin, Waldenström macroglobulinemia on zanubrutinib, and type 2 diabetes on insulin, who presents with acute vomiting, watery diarrhea, dizziness, tachycardia (heart rate 128 bpm) and borderline hypotension (blood pressure 125/43 mmHg)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Assessment and Plan

This patient requires immediate hospitalization for aggressive management of chemotherapy-induced diarrhea with hemodynamic instability, likely representing a complicated grade 3-4 gastrointestinal toxicity from her recent durvalumab/gemcitabine/cisplatin regimen.

Assessment

Primary Problem: Complicated Chemotherapy-Induced Diarrhea with Hemodynamic Compromise

The clinical picture reveals:

  • Tachycardia (HR 128) with borderline hypotension (BP 125/43, MAP ~71) indicating hypovolemia
  • Watery diarrhea one week after recent hospitalization for same symptoms
  • Associated symptoms: dizziness, palpitations, nausea, anorexia
  • Physical findings: pale conjunctivae suggesting anemia, icteric sclerae consistent with known cholangiocarcinoma
  • High-risk context: Recent chemotherapy with durvalumab/gemcitabine/cisplatin, immunocompromised state (on prednisone, zanubrutinib), diabetes on insulin

This represents grade 3-4 chemotherapy-induced diarrhea based on hemodynamic instability and recurrence despite recent treatment 1. The durvalumab label specifically notes diarrhea occurs in 10-17% of patients receiving this combination, with grade 3-4 events in 1.1-1.8% 2.

Secondary Problems:

  1. Stage IV intrahepatic cholangiocarcinoma on active palliative chemotherapy (durvalumab/gemcitabine/cisplatin) 3
  2. Waldenström macroglobulinemia on zanubrutinib
  3. Type 2 diabetes on insulin - at risk for hyperglycemia with stress/infection or hypoglycemia with poor oral intake
  4. Immunosuppression from prednisone (30mg daily total), chemotherapy, and underlying malignancies

Plan

Immediate Management (First 24 Hours)

1. Hospitalization with Intensive Monitoring

  • Admit to monitored bed given hemodynamic instability
  • Continuous cardiac monitoring for tachycardia
  • Strict intake/output monitoring
  • Vital signs every 4 hours minimum

2. Aggressive Fluid Resuscitation

  • Start IV normal saline bolus 500-1000mL over 1-2 hours, then reassess hemodynamics
  • Target MAP >65, HR <100, urine output >0.5mL/kg/hr
  • Monitor for fluid overload given potential cardiac stress

3. Immediate Pharmacologic Intervention for Diarrhea

Given grade 3-4 presentation with hemodynamic compromise, bypass loperamide and start octreotide immediately 1:

  • Octreotide 100-150 mcg subcutaneously three times daily (or IV 25-50 mcg/hr if severe dehydration persists)
  • Can escalate to 500 mcg TID if inadequate response
  • Continue until diarrhea-free for 24 hours

4. Empiric Broad-Spectrum Antibiotics

Start immediately given:

  • Immunocompromised state (chemotherapy, prednisone, malignancy)
  • Risk of bacterial translocation with severe diarrhea
  • Potential neutropenia from recent chemotherapy

Fluoroquinolone recommended 1:

  • Ciprofloxacin 400mg IV every 12 hours OR
  • Levofloxacin 500mg IV daily

5. Laboratory Workup

  • Complete blood count with differential - assess for neutropenia, anemia, thrombocytopenia (cisplatin/gemcitabine toxicity 2, 4)
  • Comprehensive metabolic panel - electrolytes (hyponatremia, hypokalemia, hypomagnesemia common with cisplatin 4), renal function, liver function
  • Stool studies:
    • Clostridium difficile toxin (PCR)
    • Bacterial culture and sensitivity
    • Ova and parasites
    • Fecal leukocytes
  • Blood cultures if fever develops
  • Capillary blood glucose given diabetes and NPO status

6. Supportive Care

  • NPO initially, advance to clear liquids as tolerated
  • Antiemetics: Ondansetron 8mg IV every 8 hours PRN
  • Electrolyte repletion as needed based on labs (anticipate hypomagnesemia, hypokalemia from cisplatin 4)

7. Diabetes Management

  • Hold oral vildagliptin while NPO
  • Continue basal insulin (Toujeo) at reduced dose (50-75% of home dose given NPO status)
  • Hold prandial insulin (Apidra) while NPO
  • Dextrose 5% in normal saline once initial resuscitation complete to prevent hypoglycemia
  • Capillary blood glucose every 4-6 hours with correction scale

8. Hold Chemotherapy

  • Discontinue all cytotoxic chemotherapy until symptoms completely resolve 1
  • Hold durvalumab until grade returns to ≤1
  • When restarting, consider dose reduction of gemcitabine/cisplatin per protocol

Ongoing Management (24-72 Hours)

9. Daily Reassessment

  • Monitor stool frequency, consistency, volume
  • Trend vital signs, fluid balance
  • Daily labs: CBC, BMP, magnesium
  • Assess for complications: sepsis, acute kidney injury (cisplatin nephrotoxicity 4), bleeding

10. Dietary Advancement Once diarrhea improving:

  • Clear liquids (Gatorade, broth) - 8-10 glasses daily
  • BRAT diet (bananas, rice, applesauce, toast)
  • Avoid: lactose, alcohol, high-osmolar supplements, caffeine
  • Small frequent meals

11. Transition to Oral Medications Once tolerating PO and diarrhea controlled:

  • May transition octreotide to oral formulation if available
  • Resume home medications as appropriate
  • Discontinue octreotide after 12-hour diarrhea-free interval 1

12. Address Underlying Malignancies

  • Continue zanubrutinib for Waldenström's if tolerating PO (no dose adjustment needed for diarrhea)
  • Continue prednisone (critical - do not abruptly discontinue given chronic use; risk of adrenal crisis)
  • Oncology consultation regarding chemotherapy resumption timing and dose modification

Disposition Planning

Discharge Criteria:

  • Hemodynamically stable (HR <100, BP stable, adequate urine output)
  • Diarrhea resolved or grade ≤1
  • Tolerating oral intake and medications
  • Electrolytes normalized
  • No evidence of infection/sepsis
  • Safe home environment with caregiver support

Discharge Instructions:

  • Dietary modifications (avoid lactose, alcohol, high-osmolar supplements)
  • Strict hand hygiene
  • Monitor stool frequency and report if >4 loose stools/day
  • Return precautions: fever, dizziness, bloody stools, inability to maintain hydration
  • Close follow-up with oncology within 1 week

Chemotherapy Modification for Future Cycles

Given recurrent grade 3-4 diarrhea:

  • Dose reduction of gemcitabine and cisplatin by 20-25% when restarting 1
  • Consider prophylactic loperamide with future cycles
  • Aggressive hydration protocols with cisplatin to minimize nephrotoxicity 4
  • Close monitoring first 2 weeks after each cycle

Critical Pitfalls to Avoid

  1. Do not use loperamide alone in grade 3-4 diarrhea with hemodynamic instability - it is ineffective and delays appropriate therapy 1
  2. Do not delay antibiotics in immunocompromised patients with severe diarrhea - bacterial translocation risk is high
  3. Do not abruptly stop prednisone - patient on chronic steroids requires continuation or stress-dose coverage
  4. Do not overlook electrolyte abnormalities - cisplatin causes significant hypomagnesemia, hypokalemia, hyponatremia 4
  5. Do not restart chemotherapy at full dose after grade 3-4 toxicity - dose reduction mandatory 1
  6. Do not forget diabetes management - NPO status with continued basal insulin risks hypoglycemia; stress/infection risks hyperglycemia

Prognosis Context

This patient has stage IV intrahepatic cholangiocarcinoma with splenic metastasis, for which the durvalumab/gemcitabine/cisplatin regimen offers median overall survival of 12.9 months 3. While this acute complication is serious, it is manageable with aggressive supportive care, and continuation of systemic therapy (with dose modification) remains appropriate for palliation and quality of life.

References

Related Questions

What is the recommended chemotherapy regimen for an adult with unresectable or metastatic cholangiocarcinoma, including first‑line and appropriate second‑line options?
What evidence supports the use of pembrolizumab (Keytruda) as third-line therapy for metastatic cholangiocarcinoma after progression on gemcitabine‑cisplatin and prior pembrolizumab?
Is chemotherapy or immunotherapy indicated and beneficial for advanced gallbladder cancer?
What is the appropriate second-line treatment for a 61-year-old woman with intrahepatic cholangiocarcinoma who has developed chemotherapy‑induced peripheral neuropathy after first‑line gemcitabine‑cisplatin?
What is the recommended second-line systemic therapy for a patient with stage IV cholangiocarcinoma who has progressed after first-line gemcitabine plus cisplatin?
What is the maximum duration and appropriate dosing of ketorolac (Toradol) for pain management, and which laboratory parameters should be monitored?
What is the appropriate workup for bilateral pitting edema?
What are the recommended spironolactone dosing regimens for hypertension, for pure diuretic effect, and for cirrhotic ascites?
How should I evaluate and manage bilateral knee pain in a patient with mixed connective tissue disease on methotrexate after bilateral total knee replacement, given negative ANA, negative rheumatoid factor, and normal C‑reactive protein?
What are the disadvantages of biologic agents?
Can I upload a photo of my herpes labialis lesion for evaluation, given it appears healed after taking valacyclovir (valacyclovir) when I experienced tingling without a blister?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.